Galecto, Inc. announced the treatment of the first patient in a Phase IIa trial of its oral LOXL2 inhibitor GB2064 in myelofibrosis. The current standard of care for myelofibrosis is JAK inhibitors, but questions remain regarding side effects caused by the mechanism of action.
[Galecto, Inc.]
7992332
{7992332:nan}
apa
50
1
165804
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
